


CORRECTION

Open Access



Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Ruoshuang Han^{1,2†}, Haoyue Guo^{1†}, Jinpeng Shi^{1†}, Sha Zhao^{1†}, Yijun Jia¹, Xiaozhen Liu¹, Yiwei Liu¹, Lei Cheng³, Chao Zhao³, Xuefei Li³ and Caicun Zhou^{1*} 

Correction: *BMC Med* 22, 174 (2024)
<https://doi.org/10.1186/s12916-024-03389-w>

The original article [1] mistakenly omitted Equal Contribution attribution for the first four authors – Ruoshang Han, Haoyue Guo, Jinpeng Shi, and Sha Zhao – due to an error from the production team that handled the manuscript.

The Equal Contribution attribution has since been restored.

Published online: 20 September 2024

Reference

1. Han R, Guo H, Shi J, et al. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer. *BMC Med.* 2024;22:174. <https://doi.org/10.1186/s12916-024-03389-w>.

[†]Ruoshuang Han, Haoyue Guo, Jinpeng Shi and Sha Zhao contributed equally to this work.

The original article can be found online at <https://doi.org/10.1186/s12916-024-03389-w>.

*Correspondence:

Caicun Zhou
caicunzhoudr@yeah.net

¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China

² Department of Oncology, The First Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China

³ Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China

